Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The BUY prediction by Finanzgonzo finished with a performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 12.179% | 12.179% | 14.874% | 5.241% |
| iShares Core DAX® | -1.020% | 0.271% | 13.941% | 56.827% |
| iShares Nasdaq 100 | -3.122% | -1.929% | 1.920% | 83.028% |
| iShares Nikkei 225® | 0.649% | 6.582% | 21.176% | 50.695% |
| iShares S&P 500 | -0.142% | -0.295% | 1.363% | 57.560% |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)